Peer-reviewed veterinary case report
Toceranib treatment outcomes for dogs with insulinoma
By Sabina Sheppard-Olivares et al.·Published in Veterinary Record Open·2022·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009–2019)
- Species:
- dog
Plain-English summary
A group of 30 dogs diagnosed with insulinoma, a type of pancreatic tumor, were treated with a medication called toceranib phosphate. Most of these dogs showed improvement, with many experiencing either complete or partial responses to the treatment. On average, the dogs lived for about 656 days after starting treatment, which is a promising outcome. The study found that larger dogs were more likely to experience disease progression, but no new side effects were reported from the medication. Overall, toceranib appears to be a beneficial option for managing insulinoma in dogs.
People also search for: dog insulinoma treatment · toceranib for dogs · pancreatic tumor in dogs · dog cancer survival rates · insulinoma symptoms in dogs
Abstract
Abstract Background Insulinomas are the most common tumour of the endocrine pancreas in dogs. These malignant tumours have a high metastatic rate and limited chemotherapeutic options. The multi‐receptor tyrosine kinase inhibitor sunitinib malate has benefit in the treatment of metastatic insulinoma in people. Toceranib phosphate, an analogous veterinary agent, may provide benefit for dogs. Methods A retrospective study describing the extent and duration of clinical outcomes and adverse events (AEs) in dogs diagnosed with insulinoma and receiving toceranib. Results Records for 30 dogs diagnosed with insulinoma and having received toceranib were identified from a medical record search of five university and eight referral hospitals. The median progression‐free interval and overall survival time were 561 days (95% confidence interval (CI): [246, 727 days]) and 656 days (95% CI: [310, 1045 days]), respectively. Of the dogs for which the canine Response evaluation criteria for solid tumours tool could be applied, the majority (66.7%) showed either a complete response, partial response or stable disease. Time to clinical progression was associated with prior intervention and type of veterinary practice. Larger dogs were at increased risk for disease progression and death. No novel AEs were reported. Conclusions Most dogs diagnosed with insulinoma and receiving toceranib appeared to have a clinical benefit. Randomised, prospective studies are needed to better elucidate and objectively quantify the potential effect and survival benefit of toceranib therapy for management of insulinoma in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/35079406